您现在位置: -医药产业 >> 研究报告 >> English reports >> English reports >> 浏览医药行业研究报告
讯:
Research Report on Chinese Antihypertensive Drugs Market Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd Published: July 2006 Format: Hardcopy and Adobe PDF Price: US$3,100 Contact: Mr. Bian chenghua Ms. Wu huifang Tel.: 86-10-68012929-2116/2101 Fax: 86-10-68012929-2008 E-mail: bianch@healthoo.com wuhf@healthoo.com //m.limatoxi.com 1 Summary 2 Categories and market overview 2.1 CCB (calcium-channel blocker) 2.2 ACEI (angiotensin-converting enzyme inhibitor) 2.3 ARBs (angiotensin Ⅱ receptor blocker) 2.4 β-blocker 2.5 α-blocker 2.6 Diuretic 2.7 Others 3 Sales analysis of the past 4 years 3.1 Market scale and growth trend 3.2 Market share and change trend 3.2.1 Sales shares of different products of Antihypertensive Drugs 3.2.2 Sales shares of different products of CCB 3.2.3 Sales shares of different products of ACEI 3.2.4 Sales shares of different products of ARBs 3.2.5 Sales shares of different products of β-blocker 3.2.6 Sales shares of different products of α-blocker 3.2.7 Sales shares of different products of diuretic 3.2.8 Others 3.3 Change about sales rank of key brands 4 Market analysis of last year 4.1 Sales shares of different products 4.2 Sales shares of different brands 4.3 Key products and competitive enterprises of CCB Amlodipine Nifedipine Felodipine Nimodipine levamlodipine Nitrendipine Nisoldipine Others 4.4 Key products and competitive enterprises of ACEI Benazepril Enalapril Captopril Lysinopril Ramipril Compound Captopril Others 4.5 Key products and competitive enterprises of ARBs Losartan Valsartan Irbesartan Telmisartan Candesartan Coumpand preparation 4.6 Key products and competitive enterprises of β-blocker 4.7 Key products and competitive enterprises of α-blocker 4.8 Key products and competitive enterprises of α-blocker 4.9 Key products and competitive enterprises of Diuretic 5 Sales analysi of key cities 6 Research and development in China 6.1 Lsit of Domestic marketd products and import procucts 6.2 Status of application and approval for Blood Thinning Drugs
|